Back to Library

HIV-1 Remission Through Stem Cell Transplant

Medicine

This article details a case study of a 63-year-old man who achieved long-term HIV-1 remission after an allogeneic hematopoietic stem cell transplant (HSCT) from a sibling donor with a specific genetic mutation (CCR5Δ32/Δ32). The study provides in-depth virological and immunological analyses, including the absence of intact HIV DNA and replication-competent virus, and highlights the significance of donor chimerism in various tissues for achieving a potential cure.

HIV Stem Cell Transplant Immunology
19 Questions Hard Ages 16+ Apr 14, 2026

Choose a Study Format

Embed This Study Set

Add this interactive study set to your website or blog — all 6 formats included.

<div data-quixly-id="1716"></div> <script src="https://www.quixlylearn.com/assets/embed/widget.js"></script>

About this Study Set

This study set covers Medicine through 19 practice questions. This article details a case study of a 63-year-old man who achieved long-term HIV-1 remission after an allogeneic hematopoietic stem cell transplant (HSCT) from a sibling donor with a specific genetic mutation (CCR5Δ32/Δ32). The study provides in-depth virological and immunological analyses, including the absence of intact HIV DNA and replication-competent virus, and highlights the significance of donor chimerism in various tissues for achieving a potential cure. Every question includes the correct answer so you can learn as you go — pick any format above to get started.

Questions & Answers

Browse all 19 questions from the HIV-1 Remission Through Stem Cell Transplant study set below. Each question shows the correct answer — select a study format above to practice interactively.

1 What is the primary method used in this study to achieve long-term HIV-1 remission?
  • A Antiretroviral therapy alone
  • B Allogeneic hematopoietic stem cell transplantation (HSCT)
  • C Gene therapy targeting HIV DNA
  • D Immunization with an HIV vaccine
2 What specific genetic mutation in the stem cell donor conferred resistance to CCR5-tropic HIV-1?
  • A CCR5wt/wt
  • B CCR5Δ32/wt
  • C CCR5Δ32/Δ32
  • D CXCR4 mutation
3 What was the age of the patient when he achieved off-treatment HIV remission, 5 years after HSCT?
  • A 44 years old
  • B 58 years old
  • C 60 years old
  • D 63 years old
4 What hematological condition was the patient treated for with HSCT?
  • A Leukemia
  • B Lymphoma
  • C Myelodysplastic syndrome
  • D Aplastic anemia
5 How long after HSCT was antiretroviral therapy (ART) discontinued in this patient?
  • A 6 months
  • B 12 months
  • C 24 months
  • D 48 months
6 What was detected in the patient's blood or gut biopsies 48 months after HSCT?
  • A Intact HIV DNA
  • B Replication-competent virus
  • C No intact HIV DNA
  • D Active HIV replication
7 Which anatomical site is identified as the primary viral reservoir for HIV?
  • A Peripheral blood
  • B Bone marrow
  • C Gut
  • D Lymph nodes
8 What does 'full donor chimerism' mean in the context of HSCT?
  • A A partial replacement of recipient cells with donor cells
  • B Complete replacement of recipient cells with donor cells
  • C The recipient's immune system rejecting the donor cells
  • D The donor's immune system attacking the recipient's cells
9 What was the outcome of the quantitative viral outgrowth assay (qVOA) performed on the patient's CD4+ T cells 48 months post-HSCT?
  • A Replication-competent viruses were detected
  • B No replication-competent viruses were detected
  • C Traces of viral DNA were found
  • D The assay was inconclusive
10 What was observed regarding HIV-specific T cell responses in the patient after HSCT?
  • A Strong HIV-specific T cell responses
  • B Normal HIV-specific T cell responses
  • C Absent HIV-specific T cell responses
  • D Variable HIV-specific T cell responses
11 What trend was observed in the patient's HIV antibody responses over time post-HSCT?
  • A Increasing antibody responses
  • B Stable antibody responses
  • C Waning antibody responses
  • D No antibody responses detected
12 Which of the following was NOT a complication experienced by the patient post-HSCT?
  • A Acute graft-versus-host disease (GvHD)
  • B Cytomegalovirus (CMV) reactivation
  • C Viral rebound of HIV
  • D Delayed B-cell reconstitution
13 What drug was used to treat the patient's acute GvHD and has also been discussed as potentially blocking HIV replication?
  • A Lenalidomide
  • B Vedolizumab
  • C Ruxolitinib
  • D Ganciclovir
14 What is a significant finding regarding donor chimerism in the gut-associated lymphoid tissues (GALT) of this patient?
  • A No donor chimerism was detected in GALT
  • B Partial donor chimerism was detected in GALT
  • C Full donor chimerism was achieved in GALT
  • D Donor chimerism in GALT was not analyzed
15 The study mentions that the CCR5Δ32 gene variant occurs most frequently in which region?
  • A Sub-Saharan Africa
  • B East Asia
  • C Northern Europe
  • D South America
16 What is a major limitation of allogeneic HSCT as a scalable strategy for HIV cure?
  • A High cost of the procedure
  • B Limited availability of suitable donors
  • C Significant procedure-related mortality
  • D Potential for drug resistance
17 The study found that intact proviral HIV DNA was undetectable in the patient's peripheral blood CD4+ T cells 48 months post-HSCT. What was detected?
  • A No HIV DNA at all
  • B Traces of total HIV DNA
  • C Active HIV replication
  • D High levels of intact proviral DNA
18 What assay was used to assess intact proviral HIV DNA?
  • A PCR
  • B Western blot
  • C ddPCR (cross-subtype intact proviral DNA assay)
  • D ELISpot
19 Which of the following HIV proteins were targeted in the western blot analysis for antibody responses?
  • A Nef, Gag, and Pol
  • B Env, Gag, and Pol
  • C Tat, Rev, and Vpu
  • D Vif, Vpr, and Nef
📱

Study on the go

Download Quixly and access all study formats on your phone — anywhere, anytime.

Download on App Store Get it on Google Play Get it on Chrome Web Store